🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats Michael Ong for the stellar talk ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). OncoAlert UroToday.com PCF Science Dan George

As shown by Michael Ong ASCO #asco25 👉 treatment escalation (SWOG Cancer Research Network Triple Switch/CCTG, and de-escalation trials have been started based on PSA response in mHSPC #prostatecancer OncoAlert UroToday.com PCF Science

⭐️The highlight of ASCO #ASCO25 👉🏼A fantastic Greek dinner thanks to the amazing Petros Grivas ! It all started with the great #BaklavaWars -an arm flex match over its true origin 1/2 OncoAlert Neeraj Agarwal, MD, FASCO

Congrats Alicia Morgans, MD, MPH for the outstanding talk ASCO #ASCO25 👉favorable health-related QOL reported by the pts in ph3 ARANOTE trial treated with darolutamide in mHSPC #prostatecancer 👇OncoAlert UroToday.com PCF Science @fredsaad

Congrats Andrew Armstrong for the 5-yr follow-up OS results from ph3 Arches trial in mHSPC #prostatecancer with enzalutamide ASCO #ASCO25 👉66% probability of survival at 5 yrs & 30% reduction of risk of death with enzalutamide👇OncoAlert UroToday.com PCF Science Arun Azad

Breaking news ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall AttardLab PCF Science UroToday.com OncoAlert

More data from the ph3 Amplitude trial ASCO #ASCO25 👉trial design, safety, subsequent therapy, rPFS in subgroups Prostate Cancer Foundation UroToday.com OncoAlert

We are grateful to our ~44,000 attendees who made #ASCO25 a success & the place to be! With nearly 40% joining us from outside the U.S., we are truly a global community united by our shared goal of improving #CancerCare & pt outcomes around the world. A heartfelt ‘thank you.’ 💗

Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but rather the body’s circadian rhythm and physiology: 1: Exercise after surgery 2: Checkpoint inhibitors in the morning

#FDA approves darolutamide for metastatic castration-sensitive #prostatecancer U.S. FDA ASCO Advanced Prostate Cancer Consensus Conference OncoAlert #ASCO25 Uromigos Oncology Brothers

Just got “accept without revisions” from Reviewer #2

Stellar presentation ASCO #ASCO25 by trailblazer Rana McKay, MD, FASCO on ETCTN trial with radium +|- olaparib in mCRPC #prostatecancer 👉rPFS ⬆️ with the combo w/wo HRRm👇Data continues to reinforce role of PARPi in rationale combinations Toni Choueiri, MD (mentor), UroToday.com OncoAlert

When you’re at a Vegas pool party but don’t want anyone to mistake you for an extrovert

Representing India, meet #Ax4 Mission Pilot Shubhanshu Shukla. ISRO

Talazoparib and enzalutamide in unselected #mCRPC patients. Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute joins Oliver Sartor, MD Mayo Clinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >

The luckiest batter in the world while batting on 98*. 😄x.com/Kushacritic/st…

The American Heart Association just published their alcohol recommendations today which line up with the report by the National Academies. Moderate EtOH intake, up to 7 drinks per week (1/day), is without risk (and may be beneficial for cardiovascular outcomes) American Heart Association

Our researchers made a strong showing at #ASCO25 —sharing bold ideas, breakthrough science, and real-world insights to improve cancer care. We’re proud of our team’s dedication to advancing research on a national stage.

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com

Excited to see our work published in Clinical Cancer Research ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team Ryon Graf, PhD Umang Swami Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert